| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 12, 2003
From the Division of Health Studies, Agency for Toxic Substances and Disease Registry (W.A.W.) and Cardiovascular Health Branch, National Center for Chronic Disease Prevention and Health Promotion (G.A.M., J.B.C.), Centers for Disease Control and Prevention, Atlanta, Ga. * To whom correspondence should be addressed. E-mail: wdw0{at}cdc.gov.
Background--Atrial fibrillation, the most common sustained disturbance of heart rhythm, is associated with a 5-fold increase in the incidence of ischemic stroke. Methods and Results--The National Hospital Discharge Survey was used to estimate the annual number and prevalence of hospitalizations with atrial fibrillation among men and women 35 years of age or older. From 1985 through 1999, hospitalizations increased from 154 086 to 376 487 for a first-listed diagnosis and from 787 750 to 2 283 673 for any diagnosis. Prevalence was higher among successive age groups. Age-standardized prevalence was consistently higher among men than women. In 1999, essential hypertension, ischemic heart disease, congestive heart failure, and diabetes were prominent coexisting conditions. The number of male patients discharged home decreased from 77% to 63%, whereas the number of discharges to long-term care increased from 9% to 15%; the corresponding values for women were 72% to 56% and 15% to 23%. A slight increase in discharges to short-term care was indicated, whereas no trends were noted for in-hospital mortality. Conclusions--Hospitalizations for atrial fibrillation have increased dramatically (2- to 3-fold) in recent years. The public health burden of atrial fibrillation is enormous and expected to continue to increase over the next decades. Primary prevention of atrial fibrillation must be recognized and pursued as a complementary management strategy for reducing cardiovascular morbidity and mortality.
Revised on May 20, 2003
Accepted on May 21, 2003
Increasing Trends in Hospitalization for Atrial Fibrillation in the United States, 1985 Through 1999. Implications for Primary Prevention
Wendy A. Wattigney MStat*,
This article has been cited by other articles:
![]() |
C. Martignani, I. Diemberger, M. Biffi, C. Valzania, M. Bertini, and G. Boriani How to assess the efficacy of catheter ablation of atrial fibrillation? Eur. Heart J., July 2, 2008; (2008) ehn300v1. [Full Text] [PDF] |
||||
![]() |
G Y H Lip and C J Boos Antithrombotic treatment in atrial fibrillation Postgrad. Med. J., May 1, 2008; 84(991): 252 - 258. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Voeller, M. S. Bailey, A. Zierer, S. C. Lall, S.-i. Sakamoto, K. Aubuchon, J. S. Lawton, N. Moazami, C. B. Huddleston, N. A. Munfakh, et al. Isolating the entire posterior left atrium improves surgical outcomes after the Cox maze procedure. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 870 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ringborg, R. Nieuwlaat, P. Lindgren, B. Jonsson, D. Fidan, A. P. Maggioni, J. Lopez-Sendon, J. Stepinska, D. V. Cokkinos, and H. J.G.M. Crijns Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation Europace, April 1, 2008; 10(4): 403 - 411. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Asbach, M. Olschewski, T. S. Faber, M. Zehender, C. Bode, and M. Brunner Mortality in patients with atrial fibrillation has significantly decreased during the last three decades: 35 years of follow-up in 1627 pacemaker patients Europace, April 1, 2008; 10(4): 391 - 394. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Voeller, R. B. Schuessler, and R. J. Damiano Jr. Surgical Treatment of Atrial Fibrillation Card. Surg. Adult, January 1, 2008; 3(2008): 1375 - 1394. [Full Text] |
||||
![]() |
F. G. Cosio, E. Aliot, G. L. Botto, H. Heidbuchel, C. J. Geller, P. Kirchhof, J.-C. De Haro, R. Frank, J. P. Villacastin, J. Vijgen, et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode Europace, January 1, 2008; 10(1): 21 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Nutescu ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2281 - 2291. [Full Text] [PDF] |
||||
![]() |
D. G. Katritsis and A. J. Camm Catheter ablation of atrial fibrillation: do we know what we are doing? Europace, November 1, 2007; 9(11): 1002 - 1005. [Full Text] [PDF] |
||||
![]() |
R. J. Damiano Jr and M. Bailey The Cox-Maze IV procedure for lone atrial fibrillation MMCTS, July 23, 2007; 2007(0723): 2758. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Lall, S. J. Melby, R. K. Voeller, A. Zierer, M. S. Bailey, T. J. Guthrie, M. R. Moon, N. Moazami, J. S. Lawton, and R. J. Damiano Jr The effect of ablation technology on surgical outcomes after the Cox-maze procedure: A propensity analysis J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 389 - 396. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Das, P. D. Willcoxson, O. J. Corrado, and R. M. West The impact of long-term warfarin on the quality of life of elderly people with atrial fibrillation Age Ageing, January 1, 2007; 36(1): 95 - 97. [Full Text] [PDF] |
||||
![]() |
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF] |
||||
![]() |
Y. Miyasaka, M. E. Barnes, B. J. Gersh, S. S. Cha, K. R. Bailey, W. P. Abhayaratna, J. B. Seward, and T. S.M. Tsang Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence Circulation, July 11, 2006; 114(2): 119 - 125. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Gollob, D. L. Jones, A. D. Krahn, L. Danis, X.-Q. Gong, Q. Shao, X. Liu, J. P. Veinot, A. S.L. Tang, A. F.R. Stewart, et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N. Engl. J. Med., June 22, 2006; 354(25): 2677 - 2688. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kehat, R. Heinrich, O. Ben-Izhak, H. Miyazaki, J. S. Gutkind, and A. Aronheim Inhibition of basic leucine zipper transcription is a major mediator of atrial dilatation Cardiovasc Res, June 1, 2006; 70(3): 543 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lafuente-Lafuente, S. Mouly, M. A. Longas-Tejero, I. Mahe, and J.-F. Bergmann Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med, April 10, 2006; 166(7): 719 - 728. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Boriani, I. Diemberger, C. Martignani, M. Biffi, and A. Branzi The epidemiological burden of atrial fibrillation: a challenge for clinicians and health care systems Eur. Heart J., April 2, 2006; 27(8): 893 - 894. [Full Text] [PDF] |
||||
![]() |
G Y H Lip and C J Boos Antithrombotic treatment in atrial fibrillation Heart, February 1, 2006; 92(2): 155 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Boos, R. A. Anderson, and G. Y.H. Lip Is atrial fibrillation an inflammatory disorder? Eur. Heart J., January 2, 2006; 27(2): 136 - 149. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Nieuwlaat, A. Capucci, A. J. Camm, S. B. Olsson, D. Andresen, D. W. Davies, S. Cobbe, G. Breithardt, J.-Y. Le Heuzey, M. H. Prins, et al. Atrial fibrillation management: a prospective survey in ESC Member Countries: The Euro Heart Survey on Atrial Fibrillation Eur. Heart J., November 2, 2005; 26(22): 2422 - 2434. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Gersh, T. S.M. Tsang, M. E. Barnes, and J. B. Seward The changing epidemiology of non-valvular atrial fibrillation: the role of novel risk factors Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C5 - C11. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Choudhury and G Y H Lip How good is anticoagulation control in non-valvar atrial fibrillation? Observations on the elderly, ethnicity, patient perceptions, and understanding of AF thromboprophylaxis Heart, April 1, 2005; 91(4): 425 - 426. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Kim and R. Arora Emerging Role of Direct Thrombin Inhibitors in Nonvalvular Atrial Fibrillation: Potential and Peril Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2005; 10(1): 11 - 21. [Abstract] [PDF] |
||||
![]() |
M. Guazzi, S. Belletti, G. Tumminello, C. Fiorentini, and M. D. Guazzi Exercise hyperventilation, dyspnea sensation, and ergoreflex activation in lone atrial fibrillation Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2899 - H2905. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. N. Singh Pursuit of Sinus Rhythm in Patients with Atrial Fibrillation: Is the Effort Worth It? Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2004; 9(4): 219 - 221. [PDF] |
||||
![]() |
T. I. Shireman, P. A. Howard, T. F. Kresowik, and E. F. Ellerbeck Combined Anticoagulant-Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation Patients Stroke, October 1, 2004; 35(10): 2362 - 2367. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. L. L'Allier, A. Ducharme, P.-F. Keller, H. Yu, M.-C. Guertin, and J.-C. Tardif Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation J. Am. Coll. Cardiol., July 7, 2004; 44(1): 159 - 164. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pacifico and P. D. Henry Ablation for atrial fibrillation: are cures really achieved? J. Am. Coll. Cardiol., June 2, 2004; 43(11): 1940 - 1942. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |